ArticleAnimal models and experimental medicine2025
A novel carcinogenic mouse model by site-directed insertion of tandem human HRAS large DNA fragment into 15E1 site.
Article in Animal models and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A novel carcinogenic mouse model by site-directed insertion of tandem human HRAS large DNA fragment into 15E1 site.Animal models and experimental medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundThe precise insertion of large DNA fragments (>3-5 kb) remains one of the key obstacles in establishment of genetically modified murine models.
methodsA 21 kb large DNA fragment containing three tandemly linked copies of the human HRAS gene was inserted into the genome of C57BL/6J mouse, generating a mouse model designated as KI.C57-ras (or named NF-hHRAS). Whole-genome sequencing and Sanger sequencing were utilized to it confirm precise insertion and copy number. The stability of transgene expression among different generations was verified from multiple aspects using by digital PCR, western blot and DNA sequencing. To assess tumor susceptibility in the mouse model, N-Nitroso-N-methylurea (MNU) was administered at a dosage of 75 mg/kg. Histopathological examinations were conducted using hematoxylin and eosin (H&E) staining.
resultsThe HRAS DNA fragment was inserted into mouse chromosome 15E1 site, locating between 80 623 202 bp and 80 625 020 bp. NF-hHRAS mice exhibited stable inheritance and displayed consistent phenotypes across individuals. Moreover, this mouse model exhibited a high susceptibility to carcinogens. Upon administration of MNU the earliest mortality onset was earlier than that of wild-type littermates (day 65 vs. day 78 for male and day 56 vs. day 84 for female). Notably, 100% of the NF-hHRAS transgenic mice developed tumors, with approximately 84% of male NF-hHRAS mice exhibiting specific tumor types, such as squamous cell carcinoma or squamous cell papilloma, which was consistent with the previously reported carcinogenic rasH2 mouse model. The types of tumors and the target organs exhibited diversity in NF-hHRAS mice, while the spontaneous tumor incidence remained low (1/50).
conclusionsThe NF-hHRAS mice demonstrated excellent genetic stability, a reproducible phenotype, and high susceptibility to carcinogens, indicating their potential utility in non-clinical safety evaluations of drugs as per the S1B guidelines issued by the ICH (The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.